Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a double blinded, randomised controlled trial that will compare atropine to placebo for postoperative pain in laparoscopic gynaecological surgery
Patients that meet eligibility criteria will receive a standardised general anesthesia based on sevoflurane and opioids and will be randomised in two groups, using computer generated randomisation system. Allocation concealment is established on opaque envelopes that contain random allocation.
Anesthesia depth will be measured by Bispectral index (BIS), titration of sevoflurane to a BIS of 45-60. In case of neuromuscular block reversal at the end of surgery, sugammadex will be administered.
At induction, 1 mg IV atropine 0.1% OR 10ml saline will be administered, depending on group allocation, on a syringe prepared by an anaesthesiologist not involved in the study.
Patients will receive ketorolac 30 mg/8h, acetaminophen 1g/8h and a morphine IV patient controlled anaesthesia pump (PCA) 0-1-8 Outcomes will be evaluated at the postoperative care unit (PACU) and 24 postoperative hours by an investigator blinded to study group
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Atropine | Experimental | Patients under a standardised general surgery will receive 1mg atropine (10ml) at induction of anesthesia |
|
| placebo | Placebo Comparator | Patients under a standardised general surgery will receive 10 ml of saline at induction of anesthesia |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Atropine | Drug | IV atropine 0.1%, 10 ml |
| |
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| 24 hours morphine consumption | morphine consumption, measured 24 post hours, in mg | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Pain Visual analog scale at 24 hours | 24 hours | |
| pain visual analog scale at postanesthesia care unit | 2 hours post | |
| number of patients with postoperative nausea and/or vomiting |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinica Santa Maria | Santiago | Chile |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
Not provided
Not provided
| ID | Term |
|---|---|
| D001285 | Atropine |
| D000077149 | Sevoflurane |
| D000077122 | Sugammadex |
| D020910 | Ketorolac |
| D000077123 | Rocuronium |
| D015742 | Propofol |
| ID | Term |
|---|---|
| D001286 | Atropine Derivatives |
| D014326 | Tropanes |
| D053961 | Azabicyclo Compounds |
| D001372 | Aza Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
IV saline, 10 ml |
|
| Sevoflurane | Drug | All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60 |
|
| sugammadex | Drug | Patients will receive sugamadex for neuromuscular reversion, if necessary |
|
| Ketorolac | Drug | 60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period |
|
| Morphine PCA | Drug | Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout |
|
| rocuronium | Drug | general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation |
|
| propofol | Drug | for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol |
|
| 24 hours |
| Patient satisfaction, on a qualitative scale | up to three days |
| number of patients that refer palpitations | 24 hours |
| number of patients that refer mouth dryness | 24 hours |
| number of patients that refer blurred vision | 24 hours |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D009930 |
| Organic Chemicals |
| D001533 | Belladonna Alkaloids |
| D012991 | Solanaceous Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D019086 | Bridged Bicyclo Compounds, Heterocyclic |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D008738 | Methyl Ethers |
| D004987 | Ethers |
| D006845 | Hydrocarbons, Fluorinated |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D047408 | gamma-Cyclodextrins |
| D003505 | Cyclodextrins |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
| D003912 | Dextrins |
| D013213 | Starch |
| D005936 | Glucans |
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |
| D007213 | Indomethacin |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D000732 | Androstanols |
| D000731 | Androstanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D010636 | Phenols |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |